Cancer, Advanced Recruiting Phase 1 / 2 Trials for Nivolumab (DB09035)

Also known as: Advanced Cancer / Cancer / Neoplasm malignant / Malignant neoplasm NOS / Cancer NOS / Malignant tumor / Malignant tumour / Cancer (NOS) / Malignant neoplasm without specification of site

IndicationStatusPhase
DBCOND0041606 (Cancer, Advanced)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03369223An Investigational Immunotherapy Study of BMS-986249 Alone and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have SpreadTreatment
NCT03110107First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Patients With Advanced Solid TumorsTreatment
NCT02658890An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have SpreadTreatment
NCT03459222An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have SpreadTreatment
NCT02737475An Investigational Immuno-therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Patients With Solid Cancers That Are Advanced or Have SpreadTreatment
NCT03792750A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid TumorsTreatment
NCT02712905An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced MalignanciesTreatment
NCT03446040An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have SpreadTreatment
NCT03661632An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid TumorsTreatment